In vitro and in vivo modelling of mutant JAK3/STAT5 signaling in leukemia
Sofia A. Omari,
Hansen J. Kosasih,
Thomas Chung,
Charles E. de Bock
Affiliations
Sofia A. Omari
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia; School of Clinical Medicine, Medicine and Health, UNSW Sydney, Sydney 2052, Australia
Hansen J. Kosasih
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia; School of Clinical Medicine, Medicine and Health, UNSW Sydney, Sydney 2052, Australia
Thomas Chung
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia; School of Clinical Medicine, Medicine and Health, UNSW Sydney, Sydney 2052, Australia
Charles E. de Bock
Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia; School of Clinical Medicine, Medicine and Health, UNSW Sydney, Sydney 2052, Australia; Corresponding author. Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney 2052, Australia.
Mutations within the IL7-R-JAK-STAT signaling pathway are important drivers of T-cell acute lymphoblastic leukemia (T-ALL). Here we describe the important steps required to generate retroviral particles for the stable expression of mutant JAK3 constructs that induce constitutive JAK/STAT signaling. These are subsequently used for the viral transduction of the IL-3 cytokine-dependent Ba/F3 cell line or murine hematopoietic stem and progenitor cells (HSPCs) for in vitro and in vivo modelling of cytokine-independent growth or leukemia initiation respectively.
